Signature Diagnostics AG

Signature Diagnostics AG is a translational oncology and genomics company based in Potsdam, Germany. Founded in 2004, Signature develops large tumor tissue and plasma biobanks in multiple cancers, including colorectal and lung cancer in the framework of large multicenter prospective clinical studies. A key aspect of the translational oncology work is Signature's biobanks with longitudinal plasma samples from cancer patients. The company also develops several next generation sequencing (NGS) assays using targeted gene panels1. Signature has expertise in developing ultra-deep sequencing tests utilizing cfDNA, which may advance the development of non-invasive treatment response monitoring for cancer patients.